Technical Data
N0023A
NAP2 (Neutrophil Activating Protein 2, CXCL7, C-X-C motif chemokine 7, PPBP, pro-platelet basic protein)
2ug
10ug
Molecular Biology Storage: -20CShipping: RT
Recombinant Human NAP-2 is a non-glycosylated, Polypeptide chain containing 70 amino acids and having a molecular mass of 7609 Dalton.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Glu-Leu-Arg-Cys

Dimers and Aggregates:
1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
NAP-2 is fully biologically active when compared to standard. The specific activity as determined by the ability of NAP-2 to chemoattract human neurotrophils using a concentration of 1-10ng/ml.

Endotoxin:
0.1ng/ug (IEU/ug) of NAP-2.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm.
2. Analysis by RP-HPLC, using a standard solution of NAP-2 as a Reference Standard.

Reconstitution:
Reconstitute the lyophilized NAP-2 in sterile 18M -cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
Source: E. coli
Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Form: Supplied as a lyophilized powder. No additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms. Rennen HJ, Frielink C, Zaat SA, J Nucl Med 2004 Jul;45(7):1217-23 2. Chemotactic activity of human blood leukocytes in plasma treated with EDTA: chemoattraction of neutrophils about monocytes is mediated by the generation of NAP-2. Malawista SE, Van Damme J, de Boisfleury Chevance A, J Leukoc Biol 2002 Jul;72(1):175-82 3. The CXC chemokine NAP-2 mediates differential heterologous desensitization of neutrophil effector functions elicited by platelet-activating factor. Schwartzkopff F, Brandt E, Flad HD, J Interferon Cytokine Res 2002 Feb;22(2):257-67 4. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes. Piccardoni P, Evangelista V, de Gaetano G, Thromb Haemost 1996 Nov;76(5):780-5 5. Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants. Ehlert JE, Petersen F, Gerdes J, J Biol Chem 1995 Mar 17;270(11):6338-44 6. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biological effects. Besemer J, J Immunol 1995 Jan 15;154(2):972-4.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.